Thomas Catinazzo - 14 Aug 2026 Form 4 Insider Report for Relay Therapeutics, Inc. (RLAY)

Reporting relationship: Chief Financial Officer
Issuer ticker: RLAY
Reported as of: 14 Aug 2026
Net transaction value: -$349,734
SEC form: 4
Accepted by SEC: 18 Aug 2026, 16:16:27 UTC
Prior SEC filing: 30 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Soo-Yeun Lim, as Attorney-in-Fact

Key filing fact

Thomas Catinazzo filed Form 4 for Relay Therapeutics, Inc. (RLAY) on 18 Aug 2026.

Key facts

This page summarizes Thomas Catinazzo's Form 4 filing for Relay Therapeutics, Inc. (RLAY).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 18 Aug 2026, 16:16.

Change

Previous filing in this sequence was filed on 30 Jul 2026.
Current net transaction value: -$349,734.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001818261 Primary reporting owner

Catinazzo Thomas

Relationship: Chief Financial Officer
Address: C/O RELAY THERAPEUTICS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE
Signature: /s/ Soo-Yeun Lim, as Attorney-in-Fact
Signature date: 18 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RLAY transaction

Common Stock

Sale

Transaction value: $349,734
Shares: -17,717
Change %: -11%
Price: $19.74
Shares after: 140,568
Date: 14 Aug 2026
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.

Footnote F2

This transaction was executed in multiple trades at prices ranging from $19.51 to $19.96. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Footnote F3

Includes 6,538 shares underlying restricted stock units.